FEDORA PHARMACEUTICALS

Fedora Pharmaceuticals, a biotechnology company, engages in the discovery and development of antibiotics for life-threatening microbial drug resistance needs. It develops beta-lactamase inhibitor molecules, which are enzymes produced by bacteria that destroy the ring structure common to beta-lactam antibiotics, such as penicillin derivatives, cephalosporins, monobactams, and carbapenems. Fedora Pharmaceuticals’s products are used in combination with various beta-lactam antibiotics for the treatment of antibiotic infections currently resistant to therapy. It began operation in 2012, with its headquarters in Edmonton in Canada.